EUVIMEDEUVIMED entdecken
Crossref

PreS1- targeting chimeric antigen receptor T cells diminish HBV infection in liver humanized FRG mice

Guilan Guo, Wenhui He, Zhongmin Zhou, Yan Diao, Jianhua Sui, Wenhui Li

Virology · 2023-09 · 586 · 23-34

DOI: 10.1016/j.virol.2023.06.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Virology, 2023-09. Verfasst von Guilan Guo und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences, Beijing Normal University, Beijing, China; National Institute of Biological Sciences, Beijing, China. Hauptthemen laut MEDLINE: Hepatitis B virus, Immunotherapy, Adoptive, Hepatitis B. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Beijing Municipal Science and Technology Commission, National Natural Science Foundation of China, Ministry of Science and Technology of the People's Republic of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current therapies control but rarely achieve a cure for hepatitis B virus (HBV) infection. Restoration of the HBV-specific immunity by cell-based therapy represents a potential approach for a cure. In this study, we generated HBV specific CAR T cells based on an antibody 2H5-A14 targeting a preS1 region of the HBV large envelope protein. We show that the A14 CAR T cell is capable of killing hepatocytes infected by HBV with high specificity; adoptive transfer of A14 CAR T cells to HBV infected humanized FRG mice resulted in reductions of all serum and intrahepatic virological markers to levels below the detection limit. A14 CAR T cells treatment increased the levels of human IFN-γ, GM-CSF, and IL-8/CXCL-8 in the mice. These results show that A14 CAR T cells may be further developed for curative therapy against HBV infection by eliminating HBV-infected hepatocytes and inducing production of pro-inflammatory and antiviral cytokines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B virusImmunotherapy, AdoptiveHepatitis BHumansAnimalsMiceLiverTransduction, GeneticLentivirusGenetic VectorsMemory T CellsReceptors, Chimeric AntigenInflammationCytokinesHepatocytesViral Envelope ProteinsHepatitis B Surface AntigensProtein Precursors

Stichwörter der Autor:innen

CAR THBVHumanized miceImmunotherapycccDNApreS1/L protein

Substanzen

Receptors, Chimeric AntigenCytokinesL protein, hepatitis B virusViral Envelope Proteinspresurface protein 1, hepatitis B surface antigenHepatitis B Surface AntigensProtein Precursors

Autor:innen und Institutionen

  • College of Life Sciences, Beijing Normal University, Beijing, China; National Institute of Biological Sciences, Beijing, China.
  • National Institute of Biological Sciences, Beijing, China.
  • National Institute of Biological Sciences, Beijing, China; Zhongshan School of Medicine, Sun Yet-Sen University, Guangzhou, China.
  • National Institute of Biological Sciences, Beijing, China; Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University, Beijing, 102206, China.
  • National Institute of Biological Sciences, Beijing, China; Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University, Beijing, 102206, China. Electronic address: liwenhui@nibs.ac.cn.

Förderung

  • Beijing Municipal Science and Technology Commission
  • National Natural Science Foundation of China
  • Ministry of Science and Technology of the People's Republic of China
  • Tsinghua University

Zitieren

APA

Guo, G., He, W., Zhou, Z., Diao, Y., Sui, J., & Li, W. (2023). PreS1- targeting chimeric antigen receptor T cells diminish HBV infection in liver humanized FRG mice. Virology, 586, 23-34. https://doi.org/10.1016/j.virol.2023.06.015

Vancouver

Guo G, He W, Zhou Z, Diao Y, Sui J, Li W. PreS1- targeting chimeric antigen receptor T cells diminish HBV infection in liver humanized FRG mice. Virology. 2023;586:23-34. doi:10.1016/j.virol.2023.06.015

BibTeX
@article{Guo2023,
  author = {Guo, Guilan and He, Wenhui and Zhou, Zhongmin and Diao, Yan and Sui, Jianhua and Li, Wenhui},
  title = {PreS1- targeting chimeric antigen receptor T cells diminish HBV infection in liver humanized FRG mice},
  journal = {Virology},
  year = {2023},
  volume = {586},
  pages = {23--34},
  doi = {10.1016/j.virol.2023.06.015}
}
Kostenlos starten →